Sarilumab

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Sarilumab
Monoclonal antibody
Type Whole antibody
Source Human
Target IL-6
Clinical data
Legal status
  • Investigational
Routes of
administration
Subcutaneous injection
Identifiers
CAS Number 1189541-98-7 N
ATC code none
KEGG D10161 N
Chemical data
Formula C6388H9918N1718O1998S44
Molecular mass 144.13 kg/mol
 NYesY (what is this?)  (verify)

Sarilumab is a human monoclonal antibody against the interleukin-6 receptor.[1]

Regeneron and Sanofi are currently co-developing the drug for the treatment of rheumatoid arthritis (RA), for which it is in phase III trials.

Development in ankylosing spondylitis has been suspended after the drug failed to show clinical benefit over methotrexate in a phase II trial.[2]

Clinical trials

On May 15, 2013, both companies announced that 2 new trials were starting (COMPARE and ASCERTAIN) and the first patients had already been enrolled.[3]

In June 2015 a phase 3 trial (with methotrexate) for RA reported meeting its 3 coprimary endpoints.[4]

In Nov 2015 the SARIL-RA-TARGET trial reported good results (meeting both its coprimary end points).[5]

See also

References

  1. Lua error in package.lua at line 80: module 'strict' not found. Needs subscription
  2. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis. July 2011
  3. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA). May 2013
  4. Lua error in package.lua at line 80: module 'strict' not found.
  5. Sarilumab effective in broad range of RA patients: Study


<templatestyles src="Asbox/styles.css"></templatestyles>

<templatestyles src="Asbox/styles.css"></templatestyles>